Amezinium (BioDeep_00000843593)
代谢物信息卡片
化学式: C11H12N3O+ (202.098)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(general) 100%
分子结构信息
SMILES: COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2
InChI: InChI=1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1
描述信息
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics
D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Yoshiyuki Toya, Toshiaki Ebina, Satoshi Umemura. [Cathecholamine].
Nihon rinsho. Japanese journal of clinical medicine.
2004 Jun; 62 Suppl 6(?):178-82. doi:
NULL. [PMID: 15250291] - Z Kokot, I Prawdzik. Determination of amezinium in plasma by RP HPLC and its application to bioequivalence studies.
Acta poloniae pharmaceutica.
2001 Sep; 58(5):315-8. doi:
NULL. [PMID: 11876436] - H Miura, K Tsuchiya, T Kubodera, H Shimamura, T Matsuoka. [An autopsy case of pure autonomic failure with pathological features of Parkinson's disease].
Rinsho shinkeigaku = Clinical neurology.
2001 Jan; 41(1):40-4. doi:
NULL. [PMID: 11433766] - O Oldenburg, M Karliova, S Koeppen, F Weber, R Erbel, T Philipp, A Kribben. [Shy-Drager syndrome: a rare cause of orthostatic hypotension].
Deutsche medizinische Wochenschrift (1946).
1999 Jan; 124(1-2):8-12. doi:
10.1055/s-2008-1062602. [PMID: 9951452] - L J Bryan-Lluka, H Seers, I Sharpe. Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats.
Naunyn-Schmiedeberg's archives of pharmacology.
1996 Apr; 353(5):536-44. doi:
10.1007/bf00169173. [PMID: 8740147] - Y Kitano, S Nomura, T Saiki, G Osawa. Leg ulceration during amezinium methylsulfate therapy for hypotension in a hemodialyzed patient with generalized vascular calcification.
Nephron.
1995; 71(1):115. doi:
10.1159/000188692. [PMID: 8538837] - H Shimoyama, J Suwata, H Saitoh, K Oguchi, S Kobayashi, Y Kawada. Changes in catecholamine level in hypotensive patients subjected to dialysis.
Nihon Jinzo Gakkai shi.
1989 Feb; 31(2):165-70. doi:
NULL. [PMID: 2739115] - K Nambu, K Yoshida, A Kagemoto, K Matsumoto, H Miyazaki, M Hashimoto, Y Esumi, Y Jin, S Gunji, M Iwabuchi. Disposition and metabolism of [14C]-amezinium metilsulfate in rats.
Arzneimittel-Forschung.
1988 Jul; 38(7):909-18. doi:
NULL. [PMID: 3207436] - K Kita, K Hirayama. Treatment of neurogenic orthostatic hypotension with amezinium metilsulfate, a new indirect sympathomimetic drug.
Neurology.
1988 Jul; 38(7):1095-9. doi:
10.1212/wnl.38.7.1095. [PMID: 3386828] - E Schömig, J Michael-Hepp, H Bönisch. Inhibition of neuronal noradrenaline uptake (uptake1) and desipramine binding by N-ethylmaleimide (NEM).
Naunyn-Schmiedeberg's archives of pharmacology.
1988 Jun; 337(6):633-6. doi:
10.1007/bf00175788. [PMID: 3216896] - D Hotz, E Brode. High-performance liquid chromatographic determination of amezinium in human plasma.
Journal of chromatography.
1983 Oct; 277(?):217-27. doi:
10.1016/s0378-4347(00)84839-2. [PMID: 6643607] - G Neugebauer, H S Kaumeier, O H Kehrhahn, H Morgenthaler. Pharmacodynamic and pharmacokinetic evaluation in man of the new sympathomimetic amezinium.
European journal of clinical pharmacology.
1983; 24(2):185-90. doi:
10.1007/bf00613815. [PMID: 6840165] - E Brode, M Hollmann, C Vollgraf. The pharmacokinetics of ameziniummetilsulfate in man. Single and repetitive oral administration of a therapeutically effective dose.
Arzneimittel-Forschung.
1983; 33(10):1491-7. doi:
NULL. [PMID: 6686052] - G G Belz, P E Aust, G Belz, E Appel, D Palm. Sympathomimetic effects of amezinium on the cardiovascular system and plasma catecholamines in man.
European journal of clinical pharmacology.
1982; 23(1):15-20. doi:
10.1007/bf01061371. [PMID: 7128668] - M Traut, E Brode, B Neumann, H Kummer. Pharmacokinetics of amezinium in rat and dog.
Arzneimittel-Forschung.
1981; 31(9a):1594-604. doi:
NULL. [PMID: 7197974] - S Kaumeier, O H Kehrhahn, H Morgenthaler, G Neugebauer. Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application.
Arzneimittel-Forschung.
1981; 31(9a):1653-7. doi:
NULL. [PMID: 7197980] - M Traut, H Morgenthaler, E Brode. Determination of amezinium in body fluids.
Arzneimittel-Forschung.
1981; 31(9a):1589-93. doi:
NULL. [PMID: 7030355] - C D Müller, J Gries, D Lenke, H J Teschendorf, H Weifenbach. Pharmacology of amezinium, a novel antihypotensive drug. V. Effect on visceral, renal, metabolic and sensory functions.
Arzneimittel-Forschung.
1981; 31(9a):1574-9. doi:
NULL. [PMID: 7197972] - M Traut, E Brode. Pharmacokinetics of amezinium in man.
Arzneimittel-Forschung.
1981; 31(9a):1605-15. doi:
NULL. [PMID: 7197975] - M Traut, H Kummer, E Brode. The fate of amezinium in humans and animals.
Arzneimittel-Forschung.
1981; 31(9a):1616-22. doi:
NULL. [PMID: 7197976]
